Cargando…

Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)

Ankaferd hemostat (Ankaferd blood stopper [ABS], Istanbul, Turkey) is a hemostatic agent affecting red blood cell-fibrinogen interactions. ABS has been traditionally used in Anatolia as a hemostatic agent for centuries. ABS contains a standardized combination of the plants namely Glycyrrhiza glabra,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciftciler, Rafiye, Ciftciler, Ali Erdinc, Malkan, Umit Yavuz, Haznedaroglu, Ibrahim C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026817/
https://www.ncbi.nlm.nih.gov/pubmed/32110403
http://dx.doi.org/10.1177/2050312120907811
_version_ 1783498749251682304
author Ciftciler, Rafiye
Ciftciler, Ali Erdinc
Malkan, Umit Yavuz
Haznedaroglu, Ibrahim C
author_facet Ciftciler, Rafiye
Ciftciler, Ali Erdinc
Malkan, Umit Yavuz
Haznedaroglu, Ibrahim C
author_sort Ciftciler, Rafiye
collection PubMed
description Ankaferd hemostat (Ankaferd blood stopper [ABS], Istanbul, Turkey) is a hemostatic agent affecting red blood cell-fibrinogen interactions. ABS has been traditionally used in Anatolia as a hemostatic agent for centuries. ABS contains a standardized combination of the plants namely Glycyrrhiza glabra, Thymus vulgaris, Alpinia officinarum, Vitis vinifera, and Urtica dioica. The hemostatic effect of ABS depends upon the quick promotion of a protein network, particularly fibrinogen gamma, in relation to the erythrocyte aggregation. The aim of this review is to indicate pharmacobiological basis and clinical backgrounds of ABS. Current perspective for using ABS is to provide hemostasis and accelerating wound healing particularly in cases which are difficult to manage. Future controlled trials are needed to elucidate the actions of ABS with in hemostasis, antithrombotic, anti-inflammatory, anti-infective, antifungal, and anti-oxidative effects.
format Online
Article
Text
id pubmed-7026817
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-70268172020-02-27 Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper) Ciftciler, Rafiye Ciftciler, Ali Erdinc Malkan, Umit Yavuz Haznedaroglu, Ibrahim C SAGE Open Med Review Paper Ankaferd hemostat (Ankaferd blood stopper [ABS], Istanbul, Turkey) is a hemostatic agent affecting red blood cell-fibrinogen interactions. ABS has been traditionally used in Anatolia as a hemostatic agent for centuries. ABS contains a standardized combination of the plants namely Glycyrrhiza glabra, Thymus vulgaris, Alpinia officinarum, Vitis vinifera, and Urtica dioica. The hemostatic effect of ABS depends upon the quick promotion of a protein network, particularly fibrinogen gamma, in relation to the erythrocyte aggregation. The aim of this review is to indicate pharmacobiological basis and clinical backgrounds of ABS. Current perspective for using ABS is to provide hemostasis and accelerating wound healing particularly in cases which are difficult to manage. Future controlled trials are needed to elucidate the actions of ABS with in hemostasis, antithrombotic, anti-inflammatory, anti-infective, antifungal, and anti-oxidative effects. SAGE Publications 2020-02-16 /pmc/articles/PMC7026817/ /pubmed/32110403 http://dx.doi.org/10.1177/2050312120907811 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review Paper
Ciftciler, Rafiye
Ciftciler, Ali Erdinc
Malkan, Umit Yavuz
Haznedaroglu, Ibrahim C
Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)
title Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)
title_full Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)
title_fullStr Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)
title_full_unstemmed Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)
title_short Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)
title_sort pharmacobiological management of hemostasis within clinical backgrounds via ankaferd hemostat (ankaferd blood stopper)
topic Review Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026817/
https://www.ncbi.nlm.nih.gov/pubmed/32110403
http://dx.doi.org/10.1177/2050312120907811
work_keys_str_mv AT ciftcilerrafiye pharmacobiologicalmanagementofhemostasiswithinclinicalbackgroundsviaankaferdhemostatankaferdbloodstopper
AT ciftcileralierdinc pharmacobiologicalmanagementofhemostasiswithinclinicalbackgroundsviaankaferdhemostatankaferdbloodstopper
AT malkanumityavuz pharmacobiologicalmanagementofhemostasiswithinclinicalbackgroundsviaankaferdhemostatankaferdbloodstopper
AT haznedarogluibrahimc pharmacobiologicalmanagementofhemostasiswithinclinicalbackgroundsviaankaferdhemostatankaferdbloodstopper